Ruibing Wang
Affiliation: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau 999078, China
Institution: University of Macau
ORCID: 0000-0001-9489-4241
Works: 210, Cited by: 7600, H-index: 50
Ruibing Wang received his B.S. degree in chemistry from Jilin University (Changchun, China) in 2002 and his Ph.D. degree in organic chemistry from Queen's University (Kingston, ON, Canada) in 2007. Due to the excellence of his Ph.D. research, his thesis was entitled the Outstanding Thesis Award by Queen’s School of Graduate Studies. Dr. Ruibing Wang has a multidisciplinary background and experience in Supramolecular Chemistry, Nanomaterials, Radiopharmaceuticals, and Interventional Medicine R&D. During his PhD studies at Queen’s University, he was among the earliest researchers to investigate a group of novel macrocyclic molecules, cucurbiturils, and their supramolecular encapsulation of various guest molecules including drug molecules for stability and water-solubility enhancement. He then moved to the Steacie Institute for Molecular Sciences at the National Research Council (NRC) of Canada as an Associate Research Officer for about two years, where he worked on fluorescent quantum dots development and studied their various applications including bioimaging. He was then invited to join Nordion (a world leader in nuclear medicine) and subsequently BTG plc (due to BTG’s acquisition of Nordion’s Targeted Therapy division, and later BTG plc was merged with Boston Scientific) as a Senior Scientist. At Nordion/BTG, he led various innovation and applied research projects around radiopharmaceuticals, nanomedicine evaluation, and interventional medicine development and worked as Technical Design Authority (TDA) for TheraSphere®, an interventional medicine for liver cancer treatment that has been approved by US FDA under HDE designation and recently introduced into the Asian market for hepatic neoplasia treatment. He joined the University of Macau as an Assistant Professor of Biomedical Sciences in 2014 and was later promoted to Associate Professor. He has published more than 210 peer-reviewed SCI papers with a total citation of about 7600 times and an H-index of 50. He has won the Macao Science and Technology Award (Natural Science Category - 3rd prize) in 2018 and UM Teaching Excellence Award in 2019, Macao Science and Technology Award (Technological Invention Category - 3rd prize) in 2020, and Macao Science and Technology Award (Natural Science Category - 2nd prize) in 2022. His research interests have mainly focused on Supramolecular Pharmaceutics and Biomaterials, as well as biomimetic medicine and cytopharmaceuticals.
Education
- B.S. Chemistry, Jilin University (2002-)
- Ph.D. Organic Chemistry, Queen's University (2007-)
Research Interests
Keywords:
Supramolecular Pharmaceutics and Biomaterials Biomimetics Cytopharmaceuticals
Topics:
Supramolecular Pharmaceutics Biomaterials Biomimetics Cytopharmaceuticals Nanomaterials Radiopharmaceuticals Interventional Medicine
Professional Links
Selected Publications
Quercetin reduces P. aeruginosa infection
Jia X, Gu M, Dai J, Wang J, Zhang Y, et al. Quercetin attenuates Pseudomonas aeruginosa-induced acute lung inflammation by inhibiting PI3K/AKT/NF-κB signaling pathway. Inflammopharmacology. 2024;32:1059. doi:10.1007/s10787-023-01416-5
Related Products
Products associated with this researcher's work:
